查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1710365

2025年骨髓恶性肿瘤检测全球市场报告

Hematologic Malignancies Detection Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 200 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年骨髓恶性肿瘤检测的市场规模将快速成长。到 2029 年，这一数字将成长至 54.6 亿美元，年复合成长率（CAGR）为 15.2%。预测期内的成长归因于医疗保健基础设施的扩张、政府倡议和资金筹措、扩大医疗保险覆盖范围以及改进的资料管理系统。预测期内的关键趋势包括提高遗传和表观遗传资料的分辨率、日益复杂的蛋白质表现谱技术、增强免疫检测技术、开发奈米材料和奈米感测器以及扩展远端医疗平台。

血癌发生率的上升预计将推动骨髓恶性肿瘤检测市场的成长。血液系统癌症包括影响血液、骨髓或淋巴系统并干扰正常血球的产生和功能的癌症。导致血癌发病率上升的因素包括人口老化和诊断技术的进步，使得能够更早、更准确地检测。有效检测骨髓恶性肿瘤对于治疗至关重要，因为它可以实现早期准确的诊断并有助于制定个人化有效的治疗策略。例如，美国专业组织白血病和淋巴瘤协会报告称，截至2024年3月，美国约有437,337人患有白血病或处于缓解期，预计2024年将诊断出约59,610例新病例。因此，血癌盛行率的上升正在刺激骨髓恶性肿瘤检测市场的扩张。

骨髓恶性肿瘤检测市场的主要企业正专注于开发先进的解决方案，例如血癌诊断测试，以提高诊断准确性和患者治疗效果。这些检查对于检测和确认白血病、淋巴瘤和多发性骨髓瘤等骨髓恶性肿瘤至关重要。例如，2023年11月，美国研究和治疗机构罗斯威尔帕克综合癌症中心推出了采用下一代基因定序技术的尖端血癌诊断测试PanHeme。 PanHeme 可以在 72 小时内识别血癌中的基因突变，这比以前的方法有了显着的改进。这种快速反应使得可以製定个人化治疗计划并使用基于特定突变的 FDA 批准的标靶治疗。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场 - 宏观经济情景，包括利率、感染疾病、地缘政治、新冠疫情、经济復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球骨髓恶性肿瘤检测PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 最终用途产业分析
  • 全球骨髓恶性肿瘤检测市场：成长率分析
  • 全球骨髓恶性肿瘤检测市场表现：规模与成长，2019-2024
  • 全球骨髓恶性肿瘤检测市场预测：规模与成长，2024-2029，2034F
  • 全球骨髓恶性肿瘤检测总目标市场（TAM）

第六章市场区隔

  • 全球骨髓恶性肿瘤检测市场类型、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）
  • 聚合酵素链锁反应
  • 免疫化学
  • 次世代定序
  • 萤光原位杂合反应
  • 其他类型
  • 全球骨髓恶性肿瘤检测市场的应用、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）
  • 多发性骨髓瘤
  • 骨髓发育不良症候群
  • 白血病
  • 骨髓增生性肿瘤
  • 淋巴瘤
  • 其他用途
  • 全球骨髓恶性肿瘤检测市场（依最终用户、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 医院
  • 专科诊所
  • 居家护理
  • 其他最终用户
  • 全球聚合酵素链锁反应骨髓恶性肿瘤检测市场区隔（按类型）、实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 即时PCR（qPCR）
  • 数位PCR
  • 逆转录PCR（RT-PCR）
  • 嵌套PCR
  • 多重PCR
  • PCR检测试剂套件
  • 全球骨髓恶性肿瘤检测市场免疫化学细分市场，依类型、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 酵素免疫分析法（ELISA）
  • 免疫组织化学（IHC）
  • 西方印渍术
  • 流式细胞技术
  • 萤光
  • 免疫组织化学染色法套件
  • 全球骨髓恶性肿瘤检测市场次世代定序细分市场（按类型、表现和预测），2019-2024 年、2024-2029 年、2034 年
  • 全基因组定序（WGS）
  • 全外EXOME定序（WES）
  • 标靶定序
  • RNA定序（RNA-Seq）
  • 液态生物检体NGS
  • 次世代定序套件
  • 全球骨髓恶性肿瘤检测市场、萤光原位杂合反应细分市场、按类型、性能和预测，2019-2024 年、2024-2029 年、2034 年
  • 染色体特异性FISH探针
  • DNA鱼
  • RNA鱼
  • 五彩斑斓的鱼
  • FISH法白血病及淋巴瘤检测套件
  • 全球骨髓恶性肿瘤检测市场，按类型细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 细胞遗传学检测
  • 基于流式细胞仪的检测
  • 磁振造影（MRI）检测
  • 高效液相层析（HPLC）
  • 质谱法检测骨髓恶性肿瘤

第七章 区域和国家分析

  • 全球骨髓恶性肿瘤检测市场：按地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球骨髓恶性肿瘤检测市场：依国家、地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

  • 骨髓恶性肿瘤检测市场：竞争格局
  • 骨髓恶性肿瘤检测市场：公司简介
    • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi-Aventis US LLC Overview, Products and Services, Strategy and Financial Analysis
    • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

  • Novartis AG
  • Becton Dickinson and Company
  • Laboratory Corporation of America Holdings
  • ICON plc
  • Agilent Technologies Inc.
  • Illumina Inc.
  • Beckman Coulter Inc.
  • Sysmex Corporation
  • Bio-Rad Laboratories Inc.
  • QIAGEN NV
  • Kite Pharma Inc.
  • ArcherDx Inc.
  • Invitae Corporation
  • NeoGenomics Laboratories Inc.
  • Tempus Labs Inc.

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

  • 2029年骨髓恶性肿瘤检测市场：提供新机会的国家
  • 2029年骨髓恶性肿瘤检测市场：细分市场带来新机会
  • 2029年骨髓恶性肿瘤检测市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第36章 附录

简介目录
Product Code: r31944

Hematologic malignancy detection involves identifying cancers that impact the blood, bone marrow, and lymphatic system, such as leukemia, lymphoma, and multiple myeloma. These types of cancers interfere with the normal production and function of blood cells.

Key methods for detecting hematologic malignancies include polymerase chain reaction (PCR), immunochemistry, next-generation sequencing, fluorescence in situ hybridization, and other techniques. PCR is a method used to amplify small DNA samples, which facilitates the analysis and detection of genetic mutations or abnormalities linked to hematologic cancers. This technique is applicable for conditions like multiple myeloma, myelodysplastic syndrome, leukemia, myeloproliferative neoplasms, and lymphoma, and is used in various settings, including hospitals, specialty clinics, and home care.

The hematologic malignancies detection market research report is one of a series of new reports from The Business Research Company that provides hematologic malignancies detection market statistics, including hematologic malignancies detection industry global market size, regional shares, competitors with a hematologic malignancies detection market share, detailed hematologic malignancies detection market segments, market trends and opportunities, and any further data you may need to thrive in the hematologic malignancies detection industry. This hematologic malignancies detection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hematologic malignancies detection market size has grown rapidly in recent years. It will grow from $2.68 $ billion in 2024 to $3.1 $ billion in 2025 at a compound annual growth rate (CAGR) of 15.6%. The growth in the historic period can be attributed to rising incidence rates of conditions, increased awareness about their importance, increased demand from both patients, supportive regulatory frameworks, and the rise of digital health technology.

The hematologic malignancies detection market size is expected to see rapid growth in the next few years. It will grow to $5.46 $ billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to expanding healthcare infrastructure, government initiatives and funding, the expansion of health insurance coverage, and improvements in data management systems. Major trends in the forecast period include enhanced resolution of genetic and epigenetic data, advanced techniques for profiling protein expressions, enhanced immunoassay techniques, the development of nanomaterials and nano sensors, and the expansion of telemedicine platforms.

The rising incidence of blood cancer is anticipated to drive the growth of the hematologic malignancy detection market. Blood cancer, which includes cancers affecting the blood, bone marrow, or lymphatic system, disrupts normal blood cell production and function. Factors contributing to the increased prevalence of blood cancer include aging populations and advancements in diagnostic techniques that enable earlier and more precise detection. Effective detection of hematologic malignancies is crucial for treatment, as it allows for early and accurate diagnosis, facilitating personalized and effective treatment strategies. For example, in March 2024, the Leukemia & Lymphoma Society, a US-based professional organization, reported that approximately 437,337 people in the US are living with or in remission from leukemia, with around 59,610 new cases expected to be diagnosed in 2024. Consequently, the growing prevalence of blood cancer is fueling the expansion of the hematologic malignancy detection market.

Leading companies in the hematologic malignancy detection market are concentrating on developing advanced solutions, such as blood cancer diagnostic tests, to improve diagnostic accuracy and patient outcomes. These tests are essential for detecting and confirming the presence of hematologic malignancies like leukemia, lymphoma, and multiple myeloma. For instance, in November 2023, Roswell Park Comprehensive Cancer Center, a US-based research and treatment facility, introduced PanHeme, a cutting-edge blood cancer diagnostic test that leverages next-generation gene sequencing technology. PanHeme identifies genetic mutations in blood cancers within 72 hours, a significant improvement over traditional methods. This rapid turnaround allows for the development of personalized treatment plans and the use of targeted FDA-approved therapies based on specific mutations.

In February 2022, Becton, Dickinson and Company, a US-based medical technology firm, acquired Cytognos S.L. for an undisclosed amount. This acquisition allows Becton, Dickinson and Company to enhance its capabilities in blood cancer diagnostics and post-treatment monitoring by leveraging Cytognos' expertise in flow cytometry and minimal residual disease detection. Cytognos S.L., based in Spain, specializes in clinical diagnostics, particularly in immune monitoring and blood cancer diagnosis solutions.

Major companies operating in the hematologic malignancies detection market are AbbVie Inc., Sanofi-Aventis U.S LLC, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Novartis AG, Becton Dickinson and Company, Laboratory Corporation of America Holdings, ICON plc, Agilent Technologies Inc., Illumina Inc., Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Kite Pharma Inc., ArcherDx Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Tempus Labs Inc., Adaptive Biotechnologies Corporation, Freenome Inc., Invivoscribe Technologies Inc., Asuragen Inc., Celldex Therapeutics Inc.

North America was the largest region in the hematologic malignancies detection market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematologic malignancies detection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hematologic malignancies detection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hematologic malignancy detection market consists of revenues earned by entities by providing services such as diagnostic testing, imaging studies, clinical evaluation, genetic counseling, and monitoring and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The hematologic malignancy detection market also includes sales of products including bone marrow aspiration and biopsy kits, flow cytometers, fluorescence in situ hybridization (FISH), and IHC staining kits. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hematologic Malignancies Detection Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hematologic malignancies detection market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hematologic malignancies detection ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hematologic malignancies detection market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Polymerase Chain Reaction; Immunochemistry; Next Generation Sequencing; Fluorescence In Situ Hybridization; Other Types
  • 2) By Application: Multiple Myeloma; Myelodysplastic Syndrome; Leukemia; Myeloproliferative Neoplasms; Lymphoma; Other Application
  • 3) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
  • Subsegments:
  • 1) By Polymerase Chain Reaction (PCR): Real-Time PCR (qPCR); Digital PCR; Reverse Transcription PCR (RT-PCR); Nested PCR; Multiplex PCR; PCR-Based Detection Kits
  • 2) By Immunochemistry: Enzyme-Linked Immunosorbent Assay (ELISA); Immunohistochemistry (IHC); Western Blotting; Flow Cytometry; Immunofluorescence; Immunohistochemical Staining Kits
  • 3) By Next Generation Sequencing (NGS): Whole Genome Sequencing (WGS); Whole Exome Sequencing (WES); Targeted Sequencing; RNA Sequencing (RNA-Seq); Liquid Biopsy NGS; Next-Generation Sequencing Kits For Hematologic Malignancies
  • 4) By Fluorescence In Situ Hybridization (FISH): Chromosome-Specific FISH Probes; DNA FISH; RNA FISH; Multicolor FISH; FISH-Based Detection Kits For Leukemia And Lymphoma
  • 5) By Other Types: Cytogenetic Testing; Cytometry-Based Detection; Magnetic Resonance Imaging (MRI) For Detection; High-Performance Liquid Chromatography (HPLC); Mass Spectrometry For Hematologic Malignancies Detection
  • Companies Mentioned: AbbVie Inc.; Sanofi-Aventis U.S LLC; Bristol-Myers Squibb Company; Thermo Fisher Scientific Inc.; Abbott Laboratories Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hematologic Malignancies Detection Market Characteristics

3. Hematologic Malignancies Detection Market Trends And Strategies

4. Hematologic Malignancies Detection Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Hematologic Malignancies Detection Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Hematologic Malignancies Detection PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Hematologic Malignancies Detection Market Growth Rate Analysis
  • 5.4. Global Hematologic Malignancies Detection Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Hematologic Malignancies Detection Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Hematologic Malignancies Detection Total Addressable Market (TAM)

6. Hematologic Malignancies Detection Market Segmentation

  • 6.1. Global Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Polymerase Chain Reaction
  • Immunochemistry
  • Next Generation Sequencing
  • Fluorescence In Situ Hybridization
  • Other Types
  • 6.2. Global Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Leukemia
  • Myeloproliferative Neoplasms
  • Lymphoma
  • Other Applications
  • 6.3. Global Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Other End-Users
  • 6.4. Global Hematologic Malignancies Detection Market, Sub-Segmentation Of Polymerase Chain Reaction, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Real-Time PCR (qPCR)
  • Digital PCR
  • Reverse Transcription PCR (RT-PCR)
  • Nested PCR
  • Multiplex PCR
  • PCR-Based Detection Kits
  • 6.5. Global Hematologic Malignancies Detection Market, Sub-Segmentation Of Immunochemistry, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunohistochemistry (IHC)
  • Western Blotting
  • Flow Cytometry
  • Immunofluorescence
  • Immunohistochemical Staining Kits
  • 6.6. Global Hematologic Malignancies Detection Market, Sub-Segmentation Of Next Generation Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Whole Genome Sequencing (WGS)
  • Whole Exome Sequencing (WES)
  • Targeted Sequencing
  • RNA Sequencing (RNA-Seq)
  • Liquid Biopsy NGS
  • Next-Generation Sequencing Kits For Hematologic Malignancies
  • 6.7. Global Hematologic Malignancies Detection Market, Sub-Segmentation Of Fluorescence In Situ Hybridization, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Chromosome-Specific FISH Probes
  • DNA FISH
  • RNA FISH
  • Multicolor FISH
  • FISH-Based Detection Kits For Leukemia And Lymphoma
  • 6.8. Global Hematologic Malignancies Detection Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cytogenetic Testing
  • Cytometry-Based Detection
  • Magnetic Resonance Imaging (MRI) For Detection
  • High-Performance Liquid Chromatography (HPLC)
  • Mass Spectrometry For Hematologic Malignancies Detection

7. Hematologic Malignancies Detection Market Regional And Country Analysis

  • 7.1. Global Hematologic Malignancies Detection Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Hematologic Malignancies Detection Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hematologic Malignancies Detection Market

  • 8.1. Asia-Pacific Hematologic Malignancies Detection Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hematologic Malignancies Detection Market

  • 9.1. China Hematologic Malignancies Detection Market Overview
  • 9.2. China Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hematologic Malignancies Detection Market

  • 10.1. India Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hematologic Malignancies Detection Market

  • 11.1. Japan Hematologic Malignancies Detection Market Overview
  • 11.2. Japan Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hematologic Malignancies Detection Market

  • 12.1. Australia Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hematologic Malignancies Detection Market

  • 13.1. Indonesia Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hematologic Malignancies Detection Market

  • 14.1. South Korea Hematologic Malignancies Detection Market Overview
  • 14.2. South Korea Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hematologic Malignancies Detection Market

  • 15.1. Western Europe Hematologic Malignancies Detection Market Overview
  • 15.2. Western Europe Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hematologic Malignancies Detection Market

  • 16.1. UK Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hematologic Malignancies Detection Market

  • 17.1. Germany Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hematologic Malignancies Detection Market

  • 18.1. France Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hematologic Malignancies Detection Market

  • 19.1. Italy Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hematologic Malignancies Detection Market

  • 20.1. Spain Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hematologic Malignancies Detection Market

  • 21.1. Eastern Europe Hematologic Malignancies Detection Market Overview
  • 21.2. Eastern Europe Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hematologic Malignancies Detection Market

  • 22.1. Russia Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hematologic Malignancies Detection Market

  • 23.1. North America Hematologic Malignancies Detection Market Overview
  • 23.2. North America Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hematologic Malignancies Detection Market

  • 24.1. USA Hematologic Malignancies Detection Market Overview
  • 24.2. USA Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hematologic Malignancies Detection Market

  • 25.1. Canada Hematologic Malignancies Detection Market Overview
  • 25.2. Canada Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hematologic Malignancies Detection Market

  • 26.1. South America Hematologic Malignancies Detection Market Overview
  • 26.2. South America Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hematologic Malignancies Detection Market

  • 27.1. Brazil Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hematologic Malignancies Detection Market

  • 28.1. Middle East Hematologic Malignancies Detection Market Overview
  • 28.2. Middle East Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hematologic Malignancies Detection Market

  • 29.1. Africa Hematologic Malignancies Detection Market Overview
  • 29.2. Africa Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hematologic Malignancies Detection Market Competitive Landscape And Company Profiles

  • 30.1. Hematologic Malignancies Detection Market Competitive Landscape
  • 30.2. Hematologic Malignancies Detection Market Company Profiles
    • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Sanofi-Aventis U.S LLC Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hematologic Malignancies Detection Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Becton Dickinson and Company
  • 31.3. Laboratory Corporation of America Holdings
  • 31.4. ICON plc
  • 31.5. Agilent Technologies Inc.
  • 31.6. Illumina Inc.
  • 31.7. Beckman Coulter Inc.
  • 31.8. Sysmex Corporation
  • 31.9. Bio-Rad Laboratories Inc.
  • 31.10. QIAGEN N.V.
  • 31.11. Kite Pharma Inc.
  • 31.12. ArcherDx Inc.
  • 31.13. Invitae Corporation
  • 31.14. NeoGenomics Laboratories Inc.
  • 31.15. Tempus Labs Inc.

32. Global Hematologic Malignancies Detection Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hematologic Malignancies Detection Market

34. Recent Developments In The Hematologic Malignancies Detection Market

35. Hematologic Malignancies Detection Market High Potential Countries, Segments and Strategies

  • 35.1 Hematologic Malignancies Detection Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Hematologic Malignancies Detection Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Hematologic Malignancies Detection Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer